Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan 19:10:67-74.
doi: 10.2147/CEOR.S153897. eCollection 2018.

A cost-effectiveness analysis of varenicline for smoking cessation using data from the EAGLES trial

Christine L Baker  1 , Guilhem Pietri  2
Affiliations

A cost-effectiveness analysis of varenicline for smoking cessation using data from the EAGLES trial

Christine L Baker et al. Clinicoecon Outcomes Res. .

Abstract

Background: The cost-effectiveness of varenicline has been demonstrated in the US health care setting using the Benefits of Smoking Cessation on Outcomes (BENESCO) model to simulate the lifetime direct costs and consequences of a hypothetical cohort of US adult smokers who make a single attempt to quit. The aim of this study was to undertake an updated cost-effectiveness analysis, using current epidemiology inputs and recently published smoking cessation data from the Evaluating Adverse Events in a Global Smoking Cessation Study (EAGLES), the largest clinical trial of smoking cessation pharmacotherapies conducted to date.

Methods: BENESCO is a Markov model simulating the effect of a single attempt to quit smoking on four smoking-related diseases: coronary heart disease, stroke, chronic obstructive lung disease, and lung cancer. Inputs were updated to include efficacy from EAGLES and newer data for the epidemiology of smoking in the US, the epidemiology and direct treatment costs of the four morbidities, and the costs of the interventions. Analyses compared varenicline, bupropion, nicotine replacement therapy (NRT) patch, and placebo with regard to the incidence of smoking-related morbidity, the incidence of smoking-related mortality, and cost-effectiveness at a time horizon from 2 years to lifetime.

Results: The study cohort comprised of 18,394,068 US adult smokers who made a single quit attempt during the first year of the model. For varenicline, there were an estimated 319,730 fewer smoking-related morbidities at the lifetime compared with placebo. Similarly, smoking-related mortality decreased by 198,240 subjects when varenicline was compared with placebo. For the same time horizon, varenicline was more effective and less costly, ie, dominant, compared with all comparators in the cost-effectiveness analysis.

Conclusion: Based on the BENESCO model, smoking cessation with varenicline results in reduced incidence of smoking-related morbidity and mortality compared with other smoking cessation interventions and remains a cost-effective strategy in the US population.

Keywords: BENESCO model; EAGLES trial; cost-effectiveness; smoking cessation; smoking-related morbidity; smoking-related mortality; varenicline.

PubMed Disclaimer

Conflict of interest statement

Disclosure Christine L Baker is an employee and stockholder of Pfizer Inc. Guilhem Pietri was an employee of PAREXEL Access Consulting, PAREXEL International, during the study; PAREXEL was a paid contractor to Pfizer in connection with the adaptation of the model and the development of this manuscript. The authors report no other conflicts of interest in this work.

References

    1. World Health Organization Economics of Tobacco Toolkit: Assessment of the Economic Costs of Smoking. 2011. [Accessed August 29, 2017]. Available from: http://apps.who.int/iris/bitstream/10665/44596/1/9789241501576_eng.pdf.
    1. World Health Organization [webpage on the Internet] Tobacco Fact sheet, No. 339. 2017. [Accessed August 29, 2017]. Available from: http://www.who.int/mediacentre/factsheets/fs339/en/
    1. Jamal A, Agaku IT, O’Connor E, King BA, Kenemer JB, Neff L. Current cigarette smoking among adults – United States, 2005–2013. MMWR Morb Mortal Wkly Rep. 2014;63(47):1108–1112. - PMC - PubMed
    1. U.S. Department of Health and Human Services . The Health Consequences of Smoking – 50 Years of Progress A Report of the Surgeon General. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
    1. Fiore MC, Jaén CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services Public Health Service; 2008.

LinkOut - more resources